HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cosmeceutical Pioneer Strivectin’s ‘Anti-Aging Solutions’ Draw Drug Claim Warning

This article was originally published in The Tan Sheet

Executive Summary

FDA cites Strivectin’s Potent Wrinkle Reducing Treatment and TL Advanced Tightening Neck Cream as unapproved drugs based on claims touting elastin-stimulating effects, skin-firming action and other structure/function benefits.

You may also be interested in...



California Federal Court: Products That Firm Skin Via Moisturization Could Be Unapproved Drugs

Plaintiff Ashley Franz’s claim that Beiersdorf’s Nivea Skin Firming Hydration Body Lotion is an unlawfully marketed drug clears the “relatively low bar of plausibility,” a California federal court determined May 21, denying the firm’s latest bid for dismissal. However, the court intriguingly suggests a motion for summary judgment could be “appropriate” before addressing class certification.

Regulatory News In Brief: House Microbeads Bill; Oregon Eyes Children’s Cosmetics; More

Rep. Frank Pallone, D-N.J., reintroduces his bill proposing a ban on personal-care products containing synthetic plastic microbeads; Oregon legislation would require ingredient reporting and reformulations from manufacturers of children’s cosmetics containing flagged chemicals. More regulatory news.

FDA Remains Focused On Cosmetics Carrying Drug Claims – OCAC Director

At the American Conference Institute’s Legal, Regulatory and Compliance Forum on Cosmetics, FDA Office of Cosmetics and Colors Director Linda Katz discussed her division’s priorities for the year. On the enforcement front, OCAC will continue to focus on cosmetic products marketed with drug claims, she said.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS123292

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel